Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Average: 2011-2025

Historic Equity Average for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $380.4 million.

  • Myriad Genetics' Equity Average fell 48.32% to $380.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.4 million, marking a year-over-year decrease of 48.32%. This contributed to the annual value of $742.1 million for FY2024, which is 11.07% down from last year.
  • Per Myriad Genetics' latest filing, its Equity Average stood at $380.4 million for Q3 2025, which was down 30.38% from $546.5 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Equity Average ranged from a high of $968.2 million in Q4 2021 and a low of $380.4 million during Q3 2025.
  • For the 3-year period, Myriad Genetics' Equity Average averaged around $699.3 million, with its median value being $733.3 million (2023).
  • Per our database at Business Quant, Myriad Genetics' Equity Average increased by 9.21% in 2022 and then crashed by 48.32% in 2025.
  • Over the past 5 years, Myriad Genetics' Equity Average (Quarterly) stood at $968.2 million in 2021, then decreased by 6.92% to $901.2 million in 2022, then dropped by 18.63% to $733.3 million in 2023, then declined by 2.30% to $716.4 million in 2024, then slumped by 48.32% to $380.4 million in 2025.
  • Its last three reported values are $380.4 million in Q3 2025, $546.5 million for Q2 2025, and $703.0 million during Q1 2025.